DOSSIER · UPDATED 18 NOV 2025

Ashvattha Therapeutics

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases.

avttx.com ↗Claim this profile
Founded
2015
Headcount
45
Open roles
0
Last raised
Series B · $50M
SECTION I · THE BRIEF

Inside Ashvattha Therapeutics

Brief #36936Updated 18 NOV 2025REDWOOD CITYMEDICAL ORGANIZATIONSSERIES B
Employbl Dossier

Ashvattha Therapeutics

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory…

Founded
2015
Headcount
45
Open roles
0
Last raised
Series B · $50M
Section II — RestrictedMembers only
  • Engineering interview process at Ashvattha Therapeutics
  • Tech stack & infrastructure choices
  • Culture & day-to-day work style
  • Why join now vs. 6 months from now
  • Hiring focus & open headcount by team
  • Comp philosophy and band context
Open Ashvattha Therapeutics briefSign in

7-day free trial · $25/mo · cancel anytime

LEADERSHIP

Founders & key people

Jeffrey ClelandJeffrey Cleland
Rangaramanujam KannanRangaramanujam Kannan
Justin Hanes
Sujatha KannanSujatha Kannan
OPEN ROLES

Hiring at Ashvattha Therapeutics

Current Job Listings

Listing 0 of 0 job openings
We don't currently have any jobs listed for this company. We suggest visiting the Jobs Search page if you are looking for exciting new tech and startup opportunities.
FUNDING

Capital raised

Total Amount Raised: $148,000,000

Ashvattha Therapeutics Funding Rounds

  • Series B

    $50,000,000

  • Series B

    $50,000,000

    Series B Investors

    Tribe Capital
    Natural Capital

  • Series B

    $69,000,000

  • Series B

    $69,000,000

    Series B Investors

    Huadong Medicine
    Natural Capital Investment Fund
    Tribe Capital
    Plum Alley

  • Convertible Note

    $22,000,000

  • Convertible Note

    $22,000,000

    Convertible Note Investors

    Natural Capital
    Sam Altman
    Philip Deutch
    Bhaskar Ghosh
    Kyle Wang
    Kingsley Advani
    Sakya Duvvuru
    Helios Capital
    Plum Alley
    Tribe Capital
    Sand Hill Angels
    Zephyr Venture Partners

  • Series A

    $7,000,000

  • Series A

    $7,000,000

    Series A Investors

    Natural Capital
    EcoR1 Capital
    Arjun Sethi
Funding info provided by Diffbot.
TAGS

Categorized in

Company Collections

These are collections Ashvattha Therapeutics is a part of. Click on the collection name to view similar companies.

Ashvattha Therapeutics' Industries

Ashvattha Therapeutics' Tech Stack

LOCATIONS

Where they work

Ashvattha Therapeutics Headquarters Location

1235 Radio Rd suite 200, Redwood City, CA, 94065

Loading map…